Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.

Authors

Katsutoshi Sato, Icahn School of Medicine at Mount Sinai
Amol A. Padgaonkar, Icahn School of Medicine at Mount Sinai
Stacey J. Baker, Icahn School of Medicine at Mount Sinai
Stephen C. Cosenza, Icahn School of Medicine at Mount Sinai
Olga Rechkoblit, Icahn School of Medicine at Mount Sinai
D.R.C. Venkata Subbaiah, Icahn School of Medicine at Mount Sinai
Josep Domingo-Domenech, Thomas Jefferson UniversityFollow
Alison Bartkowski, Icahn School of Medicine at Mount Sinai
Elisa R. Port, Mount Sinai Hospital
Aneel K. Aggarwal, Icahn School of Medicine at Mount Sinai
M. V. Ramana Reddy, Icahn School of Medicine at Mount Sinai
Hanna Y. Irie, Icahn School of Medicine at Mount Sinai
E. Premkumar Reddy, Icahn School of Medicine at Mount Sinai

Document Type

Article

Publication Date

8-3-2021

Comments

This article is the authors’ final published version in Nature Communications, Volume 12, Issue 1, August 2021, Article number 4671.

The published version is available at https://doi.org/10.1038/s41467-021-24878-z. Copyright © Sato et al.

Abstract

Triple negative breast cancer (TNBC) remains challenging because of heterogeneous responses to chemotherapy. Incomplete response is associated with a greater risk of metastatic progression. Therefore, treatments that target chemotherapy-resistant TNBC and enhance chemosensitivity would improve outcomes for these high-risk patients. Breast cancer stem cell-like cells (BCSCs) have been proposed to represent a chemotherapy-resistant subpopulation responsible for tumor initiation, progression and metastases. Targeting this population could lead to improved TNBC disease control. Here, we describe a novel multi-kinase inhibitor, 108600, that targets the TNBC BCSC population. 108600 treatment suppresses growth, colony and mammosphere forming capacity of BCSCs and induces G2M arrest and apoptosis of TNBC cells. In vivo, 108600 treatment of mice bearing triple negative tumors results in the induction of apoptosis and overcomes chemotherapy resistance. Finally, treatment with 108600 and chemotherapy suppresses growth of pre-established TNBC metastases, providing additional support for the clinical translation of this agent to clinical trials.

Recommended Citation

Sato, Katsutoshi; Padgaonkar, Amol A.; Baker, Stacey J.; Cosenza, Stephen C.; Rechkoblit, Olga; Subbaiah, D.R.C. Venkata; Domingo-Domenech, Josep; Bartkowski, Alison; Port, Elisa R.; Aggarwal, Aneel K.; Ramana Reddy, M. V.; Irie, Hanna Y.; and Premkumar Reddy, E., "Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease." (2021). Department of Medical Oncology Faculty Papers. Paper 149.
https://jdc.jefferson.edu/medoncfp/149

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

34344863

Language

English